PRIP links public support to technology maturity

One line

The second call under the Rs 5,000 crore PRIP scheme offers separate funding tracks for early and later-stage pharmaceutical and medical-technology research.

Summary

India is a major producer of generic medicines, but moving towards novel drugs, complex biosimilars, diagnostics, and medical devices requires risk capital, research infrastructure, regulatory capability, and links between laboratories and firms.

Public funding can help bridge the gap between discovery and commercialisation. It must still use transparent milestones and avoid socialising risk while privatising all gains.

PYQ pattern

UPSC can link PRIP with research and development intensity, the translational gap, clinical validation, intellectual property, affordable health technology, and the role of public finance in high-risk innovation.

Core notes

Promotion of Research and Innovation in Pharma and MedTech (PRIP) was launched in 2023 with a total outlay of Rs 5,000 crore.
The scheme combines research infrastructure and support for industry, startups, and micro, small and medium enterprises in identified priority areas.
Under the second call, the early-stage track covers projects beginning at Technology Readiness Level (TRL) 1, 2, or 3 and seeking to advance no further than TRL 5.
The later-stage track accepts projects beginning at TRL 4, 5, or 6. Assistance may reach Rs 100 crore but is capped at 35 per cent of the approved project cost, with the balance co-funded by the applicant.
The 28 August release states assistance of up to Rs 5 crore for an early-stage project. Applicants must consult the detailed scheme terms for the applicable funding share and milestone conditions.
Priority areas include new medicines, complex generics and biosimilars, and novel medical devices such as artificial-intelligence-enabled devices, software as a medical device, genetic diagnostics, robotics, telemedicine tools, and in-vitro diagnostics.
TRL indicates technological maturity. It does not by itself prove clinical safety, efficacy, affordability, or commercial viability.

Prelims lens

PRIP is administered by the Department of Pharmaceuticals.
Technology Readiness Levels run from basic principles at the low end towards demonstrated and operational technology at the high end.
Software as a Medical Device performs a medical purpose without being merely part of a hardware medical device.
A biosimilar is highly similar to an approved reference biological product; it is not the same regulatory category as a conventional small-molecule generic.

MCQ 1

With reference to the second PRIP call, consider the following statements:

Early-stage projects may begin at TRL 1, 2, or 3.
Later-stage assistance is subject to an applicant co-funding requirement.
Reaching a higher TRL automatically proves clinical safety and affordability.

Which of the statements given above are correct?

A. 1 and 2 only
B. 2 and 3 only
C. 1 and 3 only
D. 1, 2 and 3

Reveal answer

A

The two tracks are differentiated by technological maturity and financing. TRL is not a substitute for clinical, regulatory, or affordability assessment.

MCQ 2

Which one of the following best describes software as a medical device?

A. Software intended to perform a medical purpose without being merely embedded in hardware for that purpose
B. Any hospital payroll program
C. A pharmaceutical molecule delivered through an injector
D. A patent database with no medical function

Reveal answer

A

The classification turns on the intended medical function of the software, not simply its use by a healthcare organisation.

Mains

Question, 10 marks, 150 words: Public support for pharmaceutical innovation should bridge technological risk while preserving affordability and public value. Discuss.

Approach:

Explain the discovery-to-commercialisation gap and the purpose of maturity-linked funding.
Discuss research infrastructure, startup finance, clinical validation, regulation, and industry-academia links.
Examine moral hazard, weak milestones, patent concentration, affordability, and neglected diseases.
Recommend milestone-based grants, independent review, public-interest licensing, shared facilities, transparent results, and post-market evidence.